SEC Form 4 · accession 0001274644-16-000084
Ocera Therapeutics, Inc. · OCRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Byrnes
Officer — CFO and Treasurer
Period of report
Jan 6, 2016
Accepted (ET)
Jan 7, 2016 · 6:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001274644
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $2.98 | Jan 6, 2016 | A | 123,300 | A | — | Jan 5, 2026 | Common Stock | 123,300 | 123,300 | D |
| Stock Option (Right to Buy)F1,F3 | $2.98 | Jan 6, 2016 | A | 41,100 | A | — | Jan 5, 2026 | Common Stock | 41,100 | 41,100 | D |
Explanation of responses
- F1Option to purchase Common Stock granted by the Issuer pursuant to the Issuer's Third Amended and Restated 2011 Stock Option and Incentive Plan (the "Plan"), qualified under Rule 16b-3(d).
- F2The option shall vest and become exercisable in 48 equal monthly installments beginning on February 6, 2016, subject to the Reporting Person's continued service to the Issuer through each such date.
- F3The option shall vest and become exercisable, if at all, in 48 equal monthly installments beginning on February 6, 2016, if the average closing price of the Common Stock equals or exceeds $6.00 per share for 20 consecutive trading days on or before June 30, 2017, subject to the Reporting Person's continued service to the Issuer through each such date.